Background: Depression frequently accompanies Parkinson’s disease (PD) and may have a negative impact on activities of daily living, cognitive performance, and quality of life. Because of the symptom overlap between the 2 disorders, it may be difficult to recognize depression in PD. Moreover, the partially shared pathophysiology may make it difficult to treat depressive symptoms without influencing motor or cognitive function. Objective: To review the current knowledge of the epidemiology, etiology, pathophysiology, and treatment of depression in patients with Parkinson’s disease. Method: Discussion of recent studies and relevant literature. Conclusion: Not only conceptually but also in terms of etiology, pathophysiology, and treatment, the relationship between PD and depression remains a challenge. There are still many questions to be answered. In the therapeutic domain, large, placebo-controlled trials are necessary to evaluate the efficacy of antidepressant treatment and allow the development of evidence-based guidelines. (J Geriatr Psychiatry Neurol 2004; 17:120-126)
1. Marsh L.Neuropsychiatric aspects of Parkinson’s disease. Psychosomatics2000; 41:15-23.
2.
2. Hornykiewicz O.Brain neurotransmitter changes in Parkinson’s disease. In: Marsden CD, Fahn S, Eds. Movement disorders. London: Butterworths, 1982:41-58.
3.
3. Jellinger K.An overview of morphological changes in Parkinson’s disease. Adv Neurol1986; 45:1-18.
4.
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000.
5.
5. Leentjens AFG, Verhey FRJ. Depression and Parkinson’s disease: a conceptual challenge. Acta Neuropsychiatrica2002; 14:147-151.
6.
6. Price BH, Adams RD, Coyle JT. Neurology and psychiatry: closing the great divide. Neurology2000; 54:8-14.
7.
7. Goodman A.Organic unity theory: the mind-body problem revisited. Am J Psychiatry1991; 148:553-563.
8.
8. Kandel ER. A new intellectual framework for psychiatry. Am J Psychiatry1998; 155:457-470.
9.
9. Schiffer RB, Kurlan R, Rubin A, Boer S.Evidence for atypical depression in Parkinson’s disease. Am J Psychiatry1988; 145:1020-1022.
10.
10. Menza MA, Robertson-Hoffman DE, Banapace AS. Parkinson’s disease and anxiety: comorbidity with depression. Biol Psychiatry1993; 34:465-470.
11.
11. Henderson R, Kurlan R, Kersun JM, Como P.Preliminary examination of anxiety and depression in Parkinson’s disease. J Neuropsychiatry Clin Neurosci1992; 4:257-264.
12.
12. Gotham AM, Brown RG, Marsden CD. Depression in Parkinson’s disease, a quantitative and qualitative approach. J Neurol Neurosurg Psychiatry1986; 49:381-389.
13.
13. Brown RG, MacCarthy B, Gotham AM, Der GJ, Marsden CD. Depression and disability in Parkinson’s disease: a follow-up of 132 cases. Psychol Med1988; 49:381-389.
14.
14. Huber SJ, Freidenberg DL, Paulson GW, Shuttleworth CJA. The pattern of depressive symptoms varies with progression of Parkinson’s disease. J Neurol Neurosurg Psychiatry1990; 53:257-258.
15.
15. Leentjens AFG, Marinus J, Van Hilten JJ, et al. The contribution of somatic symptoms to the diagnosis of depressive disorder in Parkinson’s disease: a discriminant analytic approach. J Neuropsychiatry Clin Neurosci2003; 15:74-77.
16.
16. Hantz P, Cardoc-Davies G, Cardoc-Davies T, et al. Depression in Parkinson’s disease. Am J Psychiatry1994; 151:1010-1014.
17.
17. Tandberg E, Larsen JP, Aarsland D, Cummings JL. The occur-rence of depression in Parkinson’s disease; a community based study. Arch Neurol1996; 53:175-179.
18.
18. Beekman ATF, Copeland JRM, Prince MJ. Review of community prevalence of depression in later life. Br J Psychiatry1999; 174:307-311.
19.
19. Cummings JL. Depression and Parkinson’s disease: a review. Am J Psychiatry1992; 149:443-454.
20.
20. Hoogendijk WJG, Sommer IEC, Tissingh G, et al. Depression in Parkinson’s disease; the impact of symptom overlap on prevalence. Psychosomatics1998; 39:416-421.
21.
21. Naarding P, Leentjens AFG, Van Kooten F, Verhey FRJ. Disease-specific properties of the Hamilton rating scale for depression (HAMD) in patients with stroke, Alzheimer’s dementia and Parkinson’s disease. J Neuropsychiatry Clin Neurosci2002; 14:329-334.
22.
22. Weintraub D, Moberg PJ, Duda JE, et al. Recognition and treatment of depression in Parkinson’s disease. J Geriatr Psychiatr Neurol2003; 16:178-183.
23.
23. Leentjens AFG, Van den Akker M, Metsemakers JFM, et al. Higher incidence of depression preceding the onset of Parkinson’s disease: a register study. Mov Disord2003; 18:414-418.
24.
24. Schuurman AG, Van den Akker M, Ensinck KTJL, et al. Increased risk of Parkinson’s disease after depression: a retrospective cohort study. Neurology2002; 58:1501-1504.
25.
25. Nilsson FM, Kessing LV, Bolwig TG. Increased risk of developing Parkinson’s disease for patients with major affective disorder: a register study. Acta Psychiatr Scand2001; 104:380-386.
26.
26. Buntinx F, Kester A, Bergers J, Knottnerus JA. Is depression in the elderly followed by dementia? A retrospective cohort study based in clinical practice. Age Ageing1996; 25:231-233.
27.
27. McGee R, Williams S, Elwood M.Depression and the development of cancer: a meta-analysis. Soc Sci Med1994; 38:187-192.
28.
28. Hemingway H, Marmot M.Evidence based cardiology: psychosocial factors in the aetiology and prognosis of coronary heart disease: systematic review of prospective cohort studies. Br Med J1999; 318:1460-1467.
29.
29. Wassertheil-Smoller S, Applegate WB, Berge K, et al. Change in depression as a precursor of cardiovascular events. Arch Int Med1996; 156:553-561.
31. Leentjens AFG, Lousberg R, Verhey FRJ. Markers for depression in Parkinson’s disease. Acta Psychiatr Scand2002; 106:196-201.
32.
32. Cole SA, Woodard JL, Juncos JL, et al. Depression and disability in Parkinson’s disease. J Neuropsychiatry Clin Neurosci1996; 8:20-25.
33.
33. Santamaria J, Tolosa ES, Valles A, et al. Mental depression in untreated Parkinson’s disease of recent onset. Adv Neurol1986; 45:443-446.
34.
34. Schrag A, Jahanshahi M, Quinn NP. What contributes to depression in Parkinson’s disease?Psychol Med2001; 31:65-73.
35.
35. Starkstein S, Preziosi TJ, Bolduc PL, Robinson RG. Depression in Parkinson’s disease. J Nerv Ment Dis1990; 178:27-31.
36.
36. Tandberg E, Larsen JP, Aarsland D, Laake K, Cummings J.Risk factors for depression in Parkinson’s disease. Arch Neurol1997; 54:625-630.
37.
37. Holthoff VA, Beurhien-Baumann B, Pietrzyk U, et al. Changes in regional cerebral perfusion in depression. SPECT monitoring of response to treatment. Nervenarzt1999; 70:620-626.
38.
38. Klemm E, Danos P, Grunwald F, et al. Temporal lobe dysfunction and correlation of regional cerebral blood flow abnormalities with psychopathology in schizophrenia and major depression: a study with single photon emission computed tomography. Psychiatry Res1996; 68:1-10.
39.
39. Chemerinski E, Robinson RG. The neuropsychiatry of stroke. Psychosomatics2000; 41:5-14.
40.
40. Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized study. Eur J Neurol2003; 10:399-406.
41.
41. Corrigan MH, Denehan AQ, Wright CE, et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety2000; 11:58-65.
42.
42. De Battista C, Solvason HB, Heilig Breen JA, Schatzberg AF. Pramipexole augmentation of a selective serotonin reuptake inhibitor in the treatment of depression. J Clin Psychopharmacol2000; 20:274-275.
43.
43. Factor SA, Molho ES, Podskalny GD, Brown D.Parkinson’s disease: drug-induced states. In: Weiner WJ, Lang AE, eds. Behavioural neurology of movement disorders. Advances in neurology. Vol. 65. New York: Raven, 1995:115-138.
44.
44. Mayeux R, Stern Y, Cote L, Williams BW. Altered serotonin metabolism in depressed patients with Parkinson’s disease. Neurology1984; 34:642-646.
45.
45. Mayeux R.The “serotonergic hypothesis” for depression in Parkinson’s disease. Adv Neurol1990; 53:163-166.
46.
46. Van Praag HM, De Haen S.Central serotonergic metabolism and frequency of depression. Psychiatr Res1979; 1:219-224.
47.
47. Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry1996; 57:449-454.
48.
48. Gerber PE, Lynd LD. Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother1998; 32:692-698.
49.
49. Fibiger HC. The neurobiological substrates of depression in Parkinson’s disease: a hypothesis. Can J Neurol Sci1984; 11:105-107.
50.
50. Janowsky DS, El-Yousef MK, Davis JM, Sekerke HJ. A cholinergic-adrenergic hypothesis of mania and depression. Lancet1972; ii:632-635.
52. Van Praag HM, Asnis GM, Kahn RS. Monoamines and abnormal behaviour: a multi-aminergic perspective. Br J Psychiatry1990; 157:723-734.
53.
53. Riederer P, Birkmayer W. A new concept: brain area specific imbalance of neurotransmitters in depression syndrome: human brain studies. In: Usdin E, Sourkes TL, Youdim MBH, eds. Enzymes and neurotransmitters in mental disease. New York: John Wiley, 1980:261-279.
54.
54. Birkmayer W, Danielczy W, Neumayer E, Riederer P.The balance of biogenic amines as condition for normal behaviour. J Neural Trans1972; 33:38-45.
55.
55. Brown R, Jahanshahi M.Depression in Parkinson’s disease: a psychosocial viewpoint. In: Weiner J, Lang AE, eds. Behavioral neurology of movement disorders. Advances in neurology. Vol. 65. New York: Raven, 1995:61-84.
56.
56. Ardouin C, Pillon B, Pfeiffer E, et al. Bilateral subthalamic or pallidal stimulation for Parkinson’s disease affects neither memory nor executive functions: a consecutive series of 62 patients. Ann Neurol1999; 46:217-223.
57.
57. Martinez-Martin P, Valldeoriola F, Tolosa E, et al. Bilateral subthalamic nucleus stimulation and quality of life in advanced Parkinson’s disease. Mov Disord2002; 17:372-377.
58.
58. Krack P, Kumar R, Ardouin C, et al. Mirthful laughter induced by subthalamic nucleus stimulation. Mov Disord2001; 16:867-875.
59.
59. Romito LM, Raja M, Daniele A, et al. Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson’s disease. Mov Disord2002; 17:1371-1374.
60.
60. Kulisevsky J, Berthier ML, Gironel A, et al. Mania following deep brain stimulation for Parkinson’s disease. Neurology2002; 59:1421-1424.
61.
61. Bejjani BP, Arnulf I, Thivard L, et al. Transient acute depression by high-frequency deep-brain stimulation. N Engl J Med1999; 340:1476-1480.
62.
62. Stefurak T, Mikulis D, Mayberg M, et al. Deep brain stimulation for Parkinson’s disease dissociates mood and motor circuits: a functional MRI case study. Mov Disord2003; 18:1499-1507.
63.
63. Mayberg HS. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bull2003; 65:193-207.
64.
64. Hobson P, Holden A, Meara J.Measuring the impact of Parkinson’s disease with the Parkinson’s Disease Quality of Life questionnaire. Age Ageing1999; 28:341-346.
65.
65. Liu CY, Wang SJ, Fuh JL, et al. The correlation of depression with functional ability in Parkinson’s disease. J Neurol1997; 244:493-498.
66.
66. American Psychiatric Association. Practice guideline for major depressive disorder in adults. American Psychiatric Association practice guidelines for the treatment of psychiatric disorder. Washington, DC: American Psychiatric Association, 2000:413-495.
67.
67. Klaassen T, Verhey FRJ, Sneijders GHJM, et al. Treatment of depression in Parkinson’s disease: a meta-analysis. J Neuropsychiatry Clin Neurosci1995; 7:281-286.
68.
68. Wermuth L, Sorensen PS, Timm S, et al. Depression in idiopathic Parkinson’s disease treated with citalopram. Nord J Psychiatry1998; 52:163-169.
69.
69. Leentjens AFG, Vreeling FW, Luijckx GJ, Verhey FRJ. SSRIs in the treatment of depression in Parkinson’s disease. Int J Geriatr Psychiatry2003; 18:552-554.
70.
70. Andersen J, Aabro ENG, Hjelmsted A, Pedersen HE. Anti-depressive treatment in Parkinson’s disease; a controlled trial of the effect of nortriptyline in patients with Parkinson’s disease treated with L-DOPA. Acta Neurol Scand1980; 62:210-219.
71.
71. Goetz CG, Tanner CM, Klawans HL. Bupropion in Parkinson’s disease. Neurology1984; 34:1092-1094.
72.
72. Leentjens AFG, Verhey FRJ, Vreeling FW. Een depressieve patiente met de ziekte van Parkinson succesvol behandeld met buproprion. Ned Tijdschr Geneeskd2000; 144:2157-2159.
73.
73. Howard WT, Warnock JK. Bupropion-induced psychosis. Am J Psychiatry1999; 156:2017-2018.
74.
74. Moellentine C, Rummans T, Ahlskog JE, et al. Effectiveness of ECT in patients with parkinsonism. J Neuropsychiatry Clin Neurosci1998; 10:187-193.
75.
75. Leentjens AFG, Van den Broek WW, Vreeling FW, Honig A.Electroconvulsietherapie (ECT) als behandelmogelijkheid voor motorische symptomen van M.Parkinson. Acta Neuropsychiatrica1998; 10:22-26.
76.
76. Andersen K, Balldin J, Gottfries CG, et al. A double-blind evaluation of electroconvulsive therapy in Parkinson’s disease with “on-off” phenomena. Acta Neurol Scand1987; 76:191-199.
77.
77. Pridmore S, Yeo PT, Pasha MI. Electroconvulsive therapy for the physical signs of Parkinson’s disease without depressive disorder. J Neurol Neurosurg Psychiatry1995; 58:641-642.
78.
78. Pridmore S, Pollard C. Electroconvulsive therapy in Parkinson’s disease: a 30 month follow-up. J Neurol Neurosurg Psychiatry1996; 61:693-693.
79.
79. Movement Disorder Society Task Force. Treatment of depression in idiopathic Parkison’s disease. Mov Disord2002; 17(supp l4):S112-S119.
80.
80. Ghazi-Noori S, Chung TH, Deane KHO, et al. Therapies for depression in Parkinson’s disease. The Cochrane Library. Vol. 1. Chichester, UK: Wiley, 2004.
81.
81. Goetz CG, Leurgans S, Raman R, Stebbins GT. Objective changes in motor function during placebo treatment in PD. Neurology2000; 54:710-714.
82.
82. De la Fuente-Fernández R, Ruth TJ, Sossi V, et al. Expectation of dopamine release: mechanism of the placebo effect in Parkinson’s disease. Science2001; 293:1164-1166.
83.
83. Olanow CW, Koller WC. An algorithm for the treatment of Parkinson’s disease. Neurology1998; 50(suppl 3):S1-S57.
84.
84. Gonul AS, Aksu M.SSRI-induced parkinsonism may be an early sign of future Parkinson’s disease. J Clin Psychiatry1999; 60:410-410.
85.
85. Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of eldepryl and an antidepressant in Parkinson’s disease. Neurology1997; 48:1070-1077.
